Evidence map›Paper›PMID 33544569›Full record

ArticleACS chemical neuroscience2021

A Structure-Based Discovery Platform for BACE2 and the Development of Selective BACE Inhibitors.

Yu-Chen Yen, Annalissa M Kammeyer, Jagannadharao Tirlangi, Arun K Ghosh, Andrew D Mesecar

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yu-Chen Yen
Annalissa M Kammeyer
Jagannadharao Tirlangi
Arun K GhoshORCID 0000-0003-2472-1841
Andrew D MesecarORCID 0000-0002-1241-2577
Purdue University West Lafayette · US

Funding

Structural Biology CoreU54AG065181 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI Timothy I Richardson · 2019 to 2026
$61.3M
Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI John Tesmer · 1985 to 2026
$43.4M
SECRETASE INHIBITORS FOR TREATING ALZHEIMER'S DISEASER01AG018933 · NIA · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI TANG, JORDAN J · 2001 to 2011
$4.9M
NCI NIH HHS P30 CA023168NIA NIH HHS R01 AG018933NIA NIH HHS U54 AG065181
6 · The paper itself

Abstract

The ability to perform routine structure-guided drug design for selective BACE inhibitors has been limited because of the lack of robust platform for BACE2 expression, purification, and crystallization. To overcome this limitation, we developed a platform that produces 2-3 mg of pure BACE2 protein per liter of

Indexed as

Alzheimer DiseaseDiabetes Mellitus, Type 2Amyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesEscherichia coliHumansAmyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesBACE2 protein, humanAlzheimer’s diseaseBACE1BACE2selective inhibitorsstructure-based drug designtype II diabetes

Identifiers

PMID33544569
PMCPMC9535992
OpenAlexW3126579292

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.